Latest Payments News

EZZ Life Science Holdings Limited has announced a fully franked ordinary dividend of AUD 0.02 per share for the six months ending December 2024, signaling steady returns for shareholders.

Southern Cross Media Group has agreed to sell its remaining television assets to Seven West Media, marking its full exit from TV and a sharpened focus on audio.

Dimerix has received a US$30 million upfront payment from Amicus Therapeutics for exclusive US rights to DMX-200, a promising kidney disease therapy. The deal positions Dimerix for up to US$560 million in further milestones plus royalties, underpinning its global licensing strategy.

Spheria Emerging Companies Limited has updated its dividend distribution approach, opting to use cash dividends to buy shares on-market due to the share price falling below its post-tax NTA per share on the ex-dividend date.

BlackRock Investment Management (Australia) Limited has announced an estimated cash distribution of 32.099015 cents per unit for its iShares Core Cash ETF (BILL), with key dates scheduled throughout May 2025.

Epsilon Healthcare reports ongoing operational challenges post-voluntary administration while unveiling a new pharmacy subsidiary aimed at diversifying revenue streams and rebuilding market confidence.

Spenda Limited has responded to an ASX price query following a notable rise in its share price and trading volume, denying any undisclosed material information while confirming ongoing confidential negotiations for virtual card and funding services.

Healius Limited has announced a special fully franked dividend of AUD 0.413 per ordinary share, signaling confidence in its financial position despite the ongoing suspension of its Dividend Reinvestment Plan.

Healius Limited has announced a fully franked special dividend of 41.3 cents per share totaling approximately $300 million, alongside a new $300 million three-year syndicated bank facility replacing its previous $680 million arrangement.

Papyrus Australia has issued a revised Appendix 4C for the March 2025 quarter, correcting the treatment of $527k in R&D expenditure previously reported as cash payments. This adjustment also impacts prior monthly and quarterly cash flow reports dating back to November 2024.

Infinity Mining has executed a binding agreement to divest its Leonora Goldfields Project interest to U Resource, which will transfer it to Evergreen Lithium (ASX: EG1). Infinity retains exposure through a substantial EG1 shareholding while refocusing on its core assets.

Bio-Gene Technology Limited is progressing its development of two novel insecticidal compounds, Qcide and Flavocide, targeting major global markets with strong commercial validation and significant US Department of Defense funding.